logo

For the Inventor, By the Inventor

Los Angeles, CA, United States of America

Cytrx Corporation


USPTO Granted Patents = 28

% Expired Patents = 32.1



Trademarks = 2

Forward Citations = 438

Loading Chart...
Loading Chart...

52 inventors (with patents filed for the assignee):

goldMedal R Martin Emanuele (16 out of 29 patents)

silverMedal Mannarsamy Balasubramanian (9 out of 16 patents)

bronzeMedal Robert L Hunter (9 out of 43 patents)

4.  Paula H Culbreth (8 out of 8 patents)

5.  László Ürögdi (7 out of 15 patents)

6.  Ede Márványos (6 out of 12 patents)

7.  Carlos A Rivera-Marrero (5 out of 5 patents)

8.  Charles William Todd (5 out of 5 patents)

9.  Robert Newton Brey, Iii (5 out of 5 patents)

10.  Mark Joseph Newman (5 out of 12 patents)

11.  Zita Jegesné Csákai (4 out of 4 patents)

12.  Magdolna Bathóné Török (4 out of 4 patents)

13.  László Dénes (4 out of 4 patents)

14.  Daniel Levitt (3 out of 3 patents)

15.  László Vígh (2 out of 4 patents)


Core Competencies:
Cytotoxic Agents
Cancer Treatment
Anthracycline Formulations
Vaccine Adjuvants
Biologically Active Copolymers
Molecular Chaperones
Carboxamidine Derivatives
Pharmaceutically Effective Compounds
Growth Promotion
Antiinfective Copolymers
Microbial Binding Inhibition
Gel Composition

28 patents:

1. 10881678 - Cytotoxic agents for the treatment of cancer (2021-01-05),
2. 10328093 - Anthracycline formulations (2019-06-25),
3. 10278981 - Cytotoxic agents for the treatment of cancer (2019-05-07),
4. 7745465 - Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof (2010-06-29),
5. 7691849 - Carboxamidine derivatives and their use in the treatment of vascular diseases (2010-04-06),
6. 7550457 - Pharmaceutically effective compounds (2009-06-23),
7. 7384936 - Carboxamidine derivatives and their use in the treatment of vascular diseases (2008-06-10),
8. 7361655 - Pharmaceutically effective compounds (2008-04-22),
9. 7148239 - Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof (2006-12-12),
10. 7126002 - Pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds (2006-10-24),
11. 7045576 - Adjuvants and copolymer compositions (2006-05-16),
12. 6844001 - Adjuvants and copolymer compositions (2005-01-18),
13. RE38558 - Polyoxypropylene/polyoxyethylene copolymers with improved biological activity (2004-07-20),
14. 6747064 - Polyoxypropylene/polyoxyethylene copolymers with improved biological activity (2004-06-08),
15. 6416947 - Vaccine adjuvant and vaccine method (2002-07-09),
Cytrx Corporation is a biopharmaceutical company based in Los Angeles, California, focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company specializes in leveraging its proprietary drug delivery technologies to enhance the efficacy and safety of existing therapies. With a commitment to advancing medical science, Cytrx aims to address unmet medical needs through its research and development efforts, contributing to the evolving landscape of biopharmaceutical solutions.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

28 Patents

#65 in Los Angeles, CA

#2,846 in California

#12,009 in US

#23,262 in the World

Los Angeles, CA (US)
Los Angeles, CA, United States of America

Cytrx Corporation

Forward Citations = 438

52 inventors:

goldMedal R Martin Emanuele (16 out of 29 patents)

silverMedal Mannarsamy Balasubramanian (9 out of 16 patents)

bronzeMedal Robert L Hunter (9 out of 43 patents)

4.  Paula H Culbreth (8 out of 8 patents)

5.  László Ürögdi (7 out of 15 patents)

Please report any incorrect information to [email protected]
Loading…